ProPhase Labs' Linebacker-1 cancer therapeutic shows promising mechanisms of actions
koto_feja/E+ via Getty Images
- ProPhase Labs (NASDAQ:PRPH) is trading ~3% higher premarket after the company gave an update on the progress and development plan for Linebacker-1 (LB-1), a small molecule, multi-kinase inhibitor for hard-to-treat cancers.
- Initially intended as a co-therapy, pre-clinical data suggests that LB-1 could also be a highly effective mono-therapy, the company said.
- ProPhase collaborated with Eurofins to analyze how Linebacker-1 affects 468 cancer-relevant kinases in Q1 2023. The study revealed that many important kinase targets, including tumorigenesis pathways like the phosphoinositide 3-kinase family, were inhibited over 99%.